Korea's Hanlim, Daewoong and Pacific Pharmas Prepare Launch For Modified Actonel
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean local pharmas Hanlim Pharm, Daewoong Pharmaceutical and Pacific Pharma are gearing up to sell an incrementally modified version of Actonel (risendronate), which was originally developed by Sanofi-Aventis and has been sold in Korea by local firm Handok Pharmaceuticals
You may also be interested in...
Roche Is Latest MNC To Partner A Primary Care Product In Korea
Handok, which is partially owned by Sanofi, will sell Roche’s Madopar for Parkinson’s disease in Korea.
Merck And Hanmi Partner In First Of A Kind Deal In South Korea
SEOUL - MSD Korea, Merck's South Korea branch, will sell a combination antihypertensive in South Korea in partnership with Hanmi Pharmaceutical, marking the first case in South Korea of a multinational company co-marketing a drug developed in part by a South Korean drug manufacturer
P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.